CPA
HUMA icon

Capital Performance Advisors’s Humacyte HUMA Stock Holding History

Capital Performance Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-130
Closed -$707 – 1291
2024
Q3 		$707 Buy
+130
New +$857 ﹤0.01% 2083

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Performance Advisors's HUMA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 130 shares — an estimated $707 sold.

Capital Performance Advisors first reported a position in HUMA in Q3 2024 and held it in 1 quarter. The position peaked at $707 in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 130 Humacyte shares in Q4 2024, an estimated $707.
  • Capital Performance Advisors first reported a position in Humacyte in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Humacyte position peaked at $707 in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.